Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT06801834 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT06801834
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06801834 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Recruiting
Start date
April 4, 2025
Completion date
October 31, 2029
Enrollment
695 (estimated)
Sites
220

Conditions

As the registry lists them; a condition with its own page is linked.

extensive stage small cell lung cancer (es-sclc)